Other

Wyeth

Human Genome Sciences, Inc.

Cancer Research Technology Limited

Beatson Institute for Cancer Research

Gerard John Graham

Vikram P Patel

Theodora W Salcedo

Robert John Benjamin Nibbs

John Gerald McCafferty

Frances Rosemary Balkwill

Ian B Pragnell

Aneesh Karatt Vellatt

Peter Slavny

Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.

Anti-CXCL12 antibody molecules and their uses

The present invention relates to deletion and substitution mutant polypeptides of human chemokine &#x3b2;-7 (Ck&#x3b2;-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck&#x3b2;-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck&#x3b2;-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Chemokine &#x3b2;-7 variants

The present invention provides a Stem Cell Inhibitor (SCI) protein which comprises at least one amino acid alteration from its native form which protein does not significantly aggregate but which retains substantially unaltered stem cell inhibitory activity. The alteration is preferably a conservative subsitution of a charged amino acid residue. Such proteins may be used in treating stem cells in a patient undergoing chemotherapy.

Stem cell inhibitor

The present invention relates to deletion and substitution mutant polypeptides of human chemokine &bgr;-7 (Ck&bgr;-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck&bgr;-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck&bgr;-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Human chemokine &bgr;-7 deletion and substitution proteins

Growing community of inventors

Glasgow, United Kingdom

Gerard John Graham